North American Report

X-linked Retinitis Pigmentosa Pipeline Insight, 2021

 Breaking News
  • No posts were found

X-linked Retinitis Pigmentosa Pipeline Insight, 2021

May 05
19:42 2021
X-linked Retinitis Pigmentosa Pipeline Insight, 2021

X-linked Retinitis Pigmentosa Pipeline” report has been added to DelveInsight

 

DelveInsight’s, “X-linked Retinitis Pigmentosa – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in X-linked Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Get a free sample copy here- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight

 

X-linked Retinitis Pigmentosa Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of X-linked Retinitis Pigmentosa pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities

 

X-linked Retinitis Pigmentosa Overview

X-linked Retinitis Pigmentosa (XLRP) caused by mutations in the Retinitis Pigmentosa GTPase regulator (RPGR) gene is the most common form of recessive RP. The RPGR gene is located on the X-chromosome; this is why the disease affects men and women in a different way. XLRP affects boys and young men by initial symptoms, such as night blindness and lack of dark adaptation, within the first decade of life. In the second decade, patients usually have a reduced visual field and visual acuity, which later results in complete blindness by the third or fourth decade of life.

 

X-Linked Retinitis Pigmentosa Pipeline: Geography Covered

  • Global coverage

 

X-Linked Retinitis Pigmentosa Key Players

  • Biogen
  • MeiraGTx Limited/Janssen Pharmaceuticals
  • And many others

 

X-Linked Retinitis Pigmentosa Drugs

  • BIIB112
  • AAV-RPGR
  • And many others

 

X-Linked Retinitis Pigmentosa Symptoms

XLRP affects boys and young men by initial symptoms, such as night blindness and lack of dark adaptation, within the first decade of life. In the second decade, patients usually have a reduced visual field and visual acuity, which later results in complete blindness by the third or fourth decade of life.

 

X-linked Retinitis Pigmentosa Pipeline Report

Female carriers may also be affected with a milder form of the disease with peripheral pigmentary changes in the retina. XLRP often results in total blindness, and there is no specific treatment for this condition. Mutations in the RPGR gene can be associated with a rod-cone or cone-rod dystrophy phenotype. It is initially identified with difficulties in scotopic visual function, where there is a predominant loss of rod photoreceptors. Also, there is peripheral vision deteriorates, resulting in visual field narrowing on perimetry findings. In some cases, patients also present early cone involvement and correspondingly impaired central visual acuity during early stages of the disease.

 

X-linked Retinitis Pigmentosa Pipeline Insights

X-linked Retinitis Pigmentosa (XLRP) is an inherited condition which causes progressive vision loss predominantly in males. The condition begins with night blindness and leads to total loss in vision.

 

Get a free sample copy here- https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight

 

Table of content

Introduction

  • Executive Summary
  • X-linked Retinitis Pigmentosa: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • X-linked Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • X-linked Retinitis Pigmentosa Collaboration Deals
  • Late Stage Products (Phase II/III)
  • BIIB 112 (NSR-RPGR): Biogen
  • Mid Stage Products (Phase I/II)
  • 4D-125: 4 D Molecular Therapeutics
  • Pre-clinical and Discovery Stage Products
  • Inactive Products
  • X-linked Retinitis Pigmentosa Key Companies
  • X-linked Retinitis Pigmentosa Key Products
  • X-linked Retinitis Pigmentosa- Unmet Needs
  • X-linked Retinitis Pigmentosa- Market Drivers and Barriers
  • X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
  • X-linked Retinitis Pigmentosa Analyst Views
  • X-linked Retinitis Pigmentosa Key Companies
  • Appendix

 

What are the key questions answered?

  • How many companies are developing X-linked Retinitis Pigmentosa drugs?
  • How many X-linked Retinitis Pigmentosa drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of X-linked Retinitis Pigmentosa?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the X-linked Retinitis Pigmentosa therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for X-linked Retinitis Pigmentosa and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

 

X-Linked Retinitis Pigmentosa Research Methodology

The objective of updating DelveInsight coverage is to ensure that it represents the most up-to-date vision of the industry possible. The DelveInsight is a fully integrated solution for comprehensive intelligence on various pharmaceutical products, both in the market and in the pipeline, across the globe

 

About DelveInsight

DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of the Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.

 

Contact us

Shruti Thakur

[email protected] 

+91-9650213330

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/